1. A 69-year-old man with hypertension, chronic stable angina, and no history of heart failure or arrhythmia presents with BP 158/88 mmHg on lisinopril 40 mg daily. He reports inadequate anginal symptom control on his current regimen. His resting heart rate is 74 bpm. His physician considers adding either amlodipine or diltiazem as the second antihypertensive agent. Which of the following correctly distinguishes the clinical profiles of these two options in this specific patient?
A) Amlodipine is preferred because it provides rate control in addition to vasodilation, addressing both hypertension and angina through a single mechanism; diltiazem should be avoided in angina because its negative inotropy worsens myocardial ischemia
B) Diltiazem is contraindicated in stable angina because non-DHP CCBs worsen coronary vasospasm through their cardiac rate-slowing effect, while amlodipine specifically reverses vasospasm
C) Both agents are appropriate for angina and hypertension, but they have different clinical profiles: amlodipine (DHP) provides pure vasodilation with no cardiac rate effect — adding antihypertensive and antianginal benefit without affecting heart rate; diltiazem (non-DHP) provides vasodilation plus negative chronotropy, reducing heart rate and myocardial oxygen demand — useful when heart rate reduction is a specific therapeutic goal; the choice depends on whether rate reduction is a priority; lisinopril combined with either is acceptable, but adding diltiazem with a future beta-blocker would be contraindicated
D) Amlodipine must be combined with a beta-blocker for angina efficacy — it has no antianginal effect as monotherapy; diltiazem can be used as sole antianginal therapy only in vasospastic angina
E) Diltiazem is preferred in all patients with stable angina on an ACE inhibitor because the ACE inhibitor-diltiazem combination produces pharmacological synergy through complementary effects on coronary artery tone
ANSWER: C
Rationale:
Both amlodipine and diltiazem are effective for stable angina and hypertension, but their cardiac profiles differ importantly. Amlodipine is a dihydropyridine CCB with high vascular selectivity and minimal direct cardiac effects at therapeutic doses — it reduces peripheral and coronary vascular resistance without affecting heart rate or AV conduction. Diltiazem is a non-dihydropyridine CCB with intermediate tissue selectivity — it provides vasodilation combined with negative chronotropy, slowing the sinus rate and reducing AV conduction velocity. In stable angina, heart rate reduction is a valid therapeutic goal (reducing myocardial oxygen demand), making diltiazem particularly useful when rate control is needed simultaneously. However, diltiazem must never be combined with a beta-blocker due to additive AV nodal suppression risk. Amlodipine has no such restriction and is freely combinable with beta-blockers. Both are reasonable choices in this patient — the decision depends on whether additional heart rate reduction is clinically desired.
Option A: Option A is incorrect because amlodipine does not provide rate control; that is a non-DHP CCB property.
Option B: Option B is incorrect because diltiazem does not worsen coronary vasospasm; non-DHP CCBs are actually used in vasospastic angina.
Option D: Option D is incorrect because amlodipine does have established antianginal efficacy as monotherapy — CAMELOT demonstrated its cardiovascular benefit in stable CAD.
Option E: Option E is incorrect because there is no established pharmacological synergy between ACE inhibitors and diltiazem specifically for coronary tone beyond their independent antihypertensive effects.
2. A 63-year-old man with hypertension is referred after developing serum sodium of 122 mEq/L six weeks after starting hydrochlorothiazide (HCTZ) 25 mg daily. He is confused and lethargic. He weighs 54 kg and has a small body habitus. He drinks approximately 2 liters of water daily. His urine osmolality is elevated (concentrated urine despite low serum sodium), confirming inappropriate ADH secretion. After correcting the hyponatremia, his physician must restart antihypertensive therapy. Which of the following antihypertensive strategies is most appropriate, and what monitoring is essential?
A) Switch to amlodipine 5 mg daily — CCBs have no effect on renal sodium or water handling and carry essentially no risk of thiazide-type hyponatremia; if additional blood pressure control is needed, losartan can be added (also no hyponatremia risk); if a diuretic becomes necessary, indapamide at the lowest dose with close sodium monitoring is preferred over HCTZ given indapamide's somewhat more favorable metabolic profile; sodium should be checked at 2 weeks if any diuretic is reintroduced
B) Restart HCTZ at half the dose (12.5 mg daily) — the hyponatremia was dose-dependent and will not recur at lower doses; no additional monitoring is required
C) Switch to furosemide 20 mg daily — loop diuretics do not cause hyponatremia and are therefore universally safe in patients who have experienced thiazide-associated hyponatremia
D) Restart HCTZ 25 mg daily with concurrent fludrocortisone to offset the sodium loss — mineralocorticoid supplementation prevents thiazide hyponatremia in susceptible patients
E) Switch to spironolactone 25 mg daily — potassium-sparing diuretics do not cause hyponatremia and are the preferred antihypertensive in patients who have experienced thiazide-associated hyponatremia as a class effect
ANSWER: A
Rationale:
A patient who has experienced severe symptomatic thiazide-associated hyponatremia (sodium 122 mEq/L) with small body habitus and high fluid intake represents a high-risk profile for recurrence. The safest antihypertensive strategy avoids all thiazide-type agents and preferentially uses classes with no hyponatremia risk. Amlodipine (a CCB) and losartan (an ARB) are both excellent choices — neither affects renal sodium or water handling in the way that thiazides do. These agents together provide effective antihypertensive coverage without hyponatremia risk. If a diuretic is eventually needed for blood pressure control, indapamide at the lowest effective dose (1.25 mg) with sodium monitoring at 2 weeks is preferred over HCTZ given indapamide's more favorable metabolic profile, though hyponatremia risk persists with any thiazide-type agent in a susceptible patient.
Option B: Option B is incorrect because thiazide-associated hyponatremia is not simply dose-dependent — it reflects patient susceptibility (small body size, high fluid intake, female sex, ADH sensitivity) that persists at any dose; recurrence at lower doses is common in susceptible patients.
Option C: Option C is incorrect because while loop diuretics are less commonly associated with hyponatremia than thiazides, they can cause it through severe volume contraction stimulating ADH; they are not universally safe and are not first-line antihypertensives in normal renal function.
Option D: Option D is incorrect because fludrocortisone supplementation is not an established preventive strategy for thiazide hyponatremia and would cause sodium retention and hypertension worsening.
Option E: Option E is incorrect because while spironolactone does not cause hyponatremia through the same mechanism, it is not the preferred antihypertensive in this context — CCBs and RAAS inhibitors are the better choice for uncomplicated hypertension in this patient.
3. A 56-year-old man with confirmed bilateral adrenal hyperplasia causing primary aldosteronism presents for annual review. He has been on spironolactone 100 mg daily for two years with good blood pressure control (BP 128/78 mmHg) and normal potassium (4.2 mEq/L). He now requests to reduce the spironolactone dose because he has developed significant erectile dysfunction and decreased libido that he attributes to the medication. His eGFR is 72 mL/min/1.73m2. Which of the following management approaches is most pharmacologically appropriate?
A) Reduce spironolactone to 25 mg daily — the sexual adverse effects are dose-dependent and will resolve at lower doses while maintaining adequate mineralocorticoid receptor blockade for his bilateral adrenal hyperplasia
B) Switch to amiloride 10 mg daily — amiloride provides equivalent efficacy to spironolactone in primary aldosteronism through direct ENaC blockade and has no sex hormone receptor binding
C) Add sildenafil to his current spironolactone regimen — the erectile dysfunction should be treated symptomatically rather than by altering the primary hypertension therapy
D) Discontinue spironolactone and switch to lisinopril plus amlodipine — ACE inhibitor plus CCB combination provides equivalent blood pressure control to spironolactone in primary aldosteronism without hormonal adverse effects
E) Switch to eplerenone 50 mg twice daily — eplerenone is a selective MRA without androgen or progesterone receptor binding that will maintain mineralocorticoid receptor blockade for his primary aldosteronism while eliminating the sex hormone-mediated adverse effects; the dose requirement is higher than spironolactone due to eplerenone's approximately 40–50x lower MR potency on a per-milligram basis
ANSWER: E
Rationale:
Spironolactone's sexual adverse effects in men — erectile dysfunction, decreased libido, and gynecomastia — arise from its non-selective receptor binding. In addition to antagonizing the mineralocorticoid receptor, spironolactone binds androgen receptors (as an antagonist) and progesterone receptors, producing anti-androgenic effects that manifest as sexual dysfunction. These adverse effects are dose-related but can occur at any dose, including 25 mg. In a patient who requires ongoing MR blockade for primary aldosteronism (bilateral adrenal hyperplasia requires lifelong medical therapy since surgery is not curative) and who is experiencing intolerable sex hormone adverse effects, eplerenone is the appropriate substitution. Eplerenone is a selective MRA that does not bind androgen or progesterone receptors and therefore causes no gynecomastia, erectile dysfunction, or other sex hormone-related adverse effects. At 50 mg twice daily, eplerenone provides MR blockade roughly equivalent to spironolactone 50–100 mg daily.
Option A: Option A is incorrect because dose reduction alone frequently does not resolve sexual adverse effects — they can occur at any spironolactone dose, and inadequate dose risks loss of aldosterone control.
Option B: Option B is incorrect because amiloride blocks ENaC directly and independently of aldosterone; in primary aldosteronism, the pathology is driven by excess aldosterone activating the mineralocorticoid receptor throughout the cardiovascular system, not just the kidney; amiloride does not provide the full MR antagonism needed.
Option C: Option C is incorrect because treating the adverse effect symptomatically rather than addressing its pharmacological cause is not appropriate when a safer alternative exists.
Option D: Option D is incorrect because ACE inhibitor plus CCB does not block the mineralocorticoid receptor; this combination would not control aldosterone-mediated volume expansion, hypokalemia, or the cardiovascular effects of ongoing aldosterone excess.
4. A 71-year-old woman with isolated systolic hypertension (BP 172/68 mmHg; pulse pressure 104 mmHg) and no other cardiac history is started on chlorthalidone 12.5 mg daily. After eight weeks her BP is 158/62 mmHg — systolic has improved but remains above target, and her diastolic has fallen further. Her physician is concerned about the widened pulse pressure and the low diastolic BP of 62 mmHg before adding a second agent. Which of the following best reflects the appropriate clinical reasoning for this patient?
A) Add a beta-blocker as the second agent — reducing cardiac output will selectively lower systolic pressure without affecting the already low diastolic pressure, narrowing the pulse pressure safely
B) Add amlodipine 5 mg daily — long-acting DHP CCBs reduce peripheral arteriolar resistance, which preferentially lowers systolic pressure and pulse pressure in isolated systolic hypertension; the J-curve concern (risk of harm from low diastolic BP) is real but the threshold for harm is generally below 60–65 mmHg; at 62 mmHg, the risk of withholding treatment is greater than the risk of modest additional diastolic lowering, particularly for a patient still 18 mmHg above systolic target; titrate carefully with close monitoring
C) Withhold all additional antihypertensive therapy — diastolic BP below 65 mmHg is an absolute contraindication to adding any further antihypertensive agent in patients over 70 regardless of systolic BP elevation
D) Add verapamil 120 mg daily — non-DHP CCBs selectively lower systolic without affecting diastolic BP in isolated systolic hypertension because their cardiac rate-slowing effect reduces pulse pressure independently of vascular resistance
E) Switch from chlorthalidone to furosemide — loop diuretics preferentially lower systolic pressure in isolated systolic hypertension without the diastolic-lowering effect seen with thiazide-type agents
ANSWER: B
Rationale:
Isolated systolic hypertension with wide pulse pressure in the elderly presents a specific therapeutic challenge — the goal is to reduce elevated systolic BP while avoiding excessive diastolic lowering, which can reduce coronary perfusion pressure (coronary flow occurs predominantly during diastole). The J-curve phenomenon — where outcomes worsen below a certain diastolic threshold — is a recognized concern, particularly for coronary events, with the threshold generally estimated around 60–65 mmHg in most trial data. At 62 mmHg this patient is just above the threshold of major concern. The appropriate response is not to withhold therapy — she remains 18 mmHg above systolic target with attendant stroke, heart failure, and cognitive risk — but to add a second agent carefully with close monitoring. Amlodipine, a long-acting DHP CCB, preferentially reduces peripheral arteriolar resistance and systolic pressure in ISH and has strong evidence in elderly ISH patients (Syst-Eur trial with nitrendipine; CAMELOT demonstrating benefit in CAD).
Option A: Option A is incorrect because beta-blockers reduce cardiac output and heart rate but do not selectively lower systolic pressure — they may lower diastolic further and may cause harm in elderly patients with stiff arteries.
Option C: Option C is incorrect because a diastolic of 62 mmHg with systolic 158 mmHg is not an absolute contraindication to further treatment; guidelines support continued treatment with careful monitoring, not withholding.
Option D: Option D is incorrect because verapamil does not selectively lower systolic without affecting diastolic in ISH; this distinction is not an established property of non-DHP CCBs, and verapamil carries constipation and drug interaction risks.
Option E: Option E is incorrect because furosemide does not preferentially lower systolic over diastolic in ISH and has no outcome trial evidence in this population.
5. A 48-year-old woman with hypertension develops acute gout in her left knee two weeks after starting chlorthalidone 25 mg daily for recently diagnosed stage 2 hypertension. Her serum uric acid is 9.2 mg/dL. Her BP prior to treatment was 158/96 mmHg and she has no other cardiovascular risk factors, no CKD, no diabetes, and no heart failure. Her physician reassesses the antihypertensive regimen. Which of the following is the most appropriate management strategy?
A) Continue chlorthalidone and add allopurinol — thiazide-induced hyperuricemia is not a contraindication to continuing the diuretic; allopurinol will control the uric acid and chlorthalidone remains the most evidence-based first-line agent for stage 2 hypertension
B) Switch to indapamide 1.25 mg daily — indapamide has a more favorable metabolic profile than chlorthalidone with less hyperuricemia at low doses and should replace chlorthalidone in patients who develop gout
C) Switch to furosemide 20 mg daily — loop diuretics do not cause hyperuricemia and are the preferred diuretic in patients who develop gout on thiazide therapy
D) Discontinue chlorthalidone and initiate losartan 50 mg daily — losartan is uniquely uricosuric among ARBs through URAT1 inhibition, providing effective antihypertensive treatment while actively lowering serum uric acid; if additional BP control is needed, amlodipine (uric acid-neutral) can be added as a second agent; allopurinol or colchicine should address the acute gout episode
E) Continue chlorthalidone and add colchicine only for the acute gout episode — uric acid elevation from thiazides does not carry the same cardiovascular risk as idiopathic hyperuricemia and does not require drug discontinuation or urate-lowering therapy
ANSWER: D
Rationale:
This patient has developed acute gout — not just asymptomatic hyperuricemia — on chlorthalidone. She has no compelling indication for a thiazide specifically (no HF, no resistant HTN requiring diuretic-based therapy) and has alternatives available that are equally or more appropriate given her complication. Losartan is the optimal replacement: it is an ARB with established antihypertensive efficacy and the unique uricosuric property of URAT1 inhibition in the proximal tubule, which will actively lower serum uric acid and reduce gout recurrence risk — pharmacologically addressing both clinical problems simultaneously. Amlodipine is a uric acid-neutral second agent if additional BP control is needed. The acute gout episode requires appropriate treatment (colchicine, NSAIDs, or glucocorticoids depending on contraindications).
Option A: Option A is incorrect because continuing chlorthalidone in a patient who has just had a gout flare from it — when better alternatives exist — is not the optimal approach; the diuretic is causing the problem, and allopurinol is additive rather than addressing the root cause.
Option B: Option B is incorrect because indapamide, while having a slightly more favorable metabolic profile than chlorthalidone or HCTZ, still causes hyperuricemia through the same tubular mechanisms at antihypertensive doses — it is not the correct solution for a patient with acute gout from a thiazide.
Option C: Option C is incorrect because loop diuretics cause hyperuricemia through the same proximal tubular secretion competition mechanism as thiazides; switching to furosemide does not solve the uric acid problem.
Option E: Option E is incorrect because acute gout is a symptomatic complication requiring management and ideally prevention; the clinical guideline recommendation in a patient with gout triggered by a thiazide is to consider switching to a uricosuric or uric acid-neutral agent when feasible.
6. A 77-year-old man with hypertension, stage 3b CKD (eGFR 32 mL/min/1.73m2), and no proteinuria presents with BP 164/88 mmHg. He is on lisinopril 20 mg daily and his BP has been difficult to control. His potassium is 5.1 mEq/L and sodium is 138 mEq/L. His physician wants to add a diuretic for additional blood pressure control. Which of the following diuretic choices is most appropriate given his renal function and potassium?
A) Add chlorthalidone 12.5 mg daily — thiazide-type diuretics retain adequate efficacy at this eGFR and are preferred over loop diuretics for hypertension management at all stages of CKD
B) Add spironolactone 25 mg daily — mineralocorticoid receptor antagonism provides the most effective additional blood pressure reduction in CKD-associated hypertension regardless of potassium level
C) Add torsemide 5 mg daily — at eGFR 32 mL/min/1.73m2 thiazide efficacy is substantially reduced and a loop diuretic is the appropriate diuretic choice; torsemide is preferred over furosemide due to its more predictable oral bioavailability and once-daily dosing; the potassium of 5.1 mEq/L on lisinopril warrants monitoring but loop diuretics will tend to lower potassium — in the context of lisinopril this may paradoxically be safer than adding a potassium-neutral or potassium-retaining agent; monitor electrolytes at 2 weeks
D) Add hydrochlorothiazide 25 mg daily — HCTZ retains adequate efficacy down to eGFR 20 mL/min/1.73m2 and is preferred for hypertension at all CKD stages due to its longer outcome trial evidence base
E) Add amiloride 5 mg daily — potassium-sparing diuretics are safe in advanced CKD and are the preferred add-on diuretic when potassium is already elevated on RAAS inhibition
ANSWER: C
Rationale:
At eGFR 32 mL/min/1.73m2 (stage 3b CKD), thiazide-type diuretics have substantially reduced efficacy. Thiazides require adequate tubular secretion for delivery to the NCC transporter in the distal convoluted tubule; at this eGFR, reduced tubular secretion limits drug delivery and reduced nephron mass further limits the natriuretic response. The appropriate diuretic transition to loop diuretics occurs at approximately eGFR 30 mL/min/1.73m2 — this patient is right at that threshold. Torsemide is preferred over furosemide for outpatient use because of its more predictable oral bioavailability (~80% vs. furosemide's highly variable ~50%) and once-daily dosing suitability. His potassium of 5.1 mEq/L on lisinopril is borderline elevated — adding a loop diuretic, which causes potassium wasting, may be beneficial in this context by modestly lowering potassium toward the normal range, though monitoring is essential.
Option A: Option A is incorrect because chlorthalidone's efficacy is substantially reduced at eGFR 32; while indapamide retains slightly better efficacy than HCTZ or chlorthalidone at this eGFR range, torsemide is the more reliable choice at this degree of renal impairment.
Option B: Option B is incorrect because spironolactone with a potassium already at 5.1 mEq/L on lisinopril in stage 3b CKD creates significant hyperkalemia risk and is not appropriate as the primary diuretic add-on in this situation.
Option D: Option D is incorrect because HCTZ does not retain adequate efficacy down to eGFR 20; its threshold for meaningful efficacy loss is approximately eGFR 30–45, and at eGFR 32 it is unreliable.
Option E: Option E is incorrect because amiloride with potassium already at 5.1 mEq/L on RAAS inhibition in advanced CKD creates extreme hyperkalemia risk — potassium-sparing diuretics are contraindicated in this context.
7. A 52-year-old woman with hypertension on lisinopril 40 mg, amlodipine 10 mg, and chlorthalidone 25 mg daily has BP of 168/102 mmHg despite confirmed adherence. Aldosterone-to-renin ratio (ARR) is 28 (borderline; formal primary aldosteronism not confirmed). Plasma renin activity is low. Potassium is 3.6 mEq/L. eGFR is 71 mL/min/1.73m2. Secondary causes other than possible subclinical aldosterone excess have been excluded. PATHWAY-2 is cited by her physician as the evidence base for adding a fourth-line agent. Which of the following correctly applies the PATHWAY-2 evidence to this patient?
A) Add spironolactone 25 mg daily — PATHWAY-2 established spironolactone as the most effective fourth-line agent in resistant hypertension, and her low PRA (indicating volume-dependent, aldosterone-mediated physiology) specifically predicts robust response; her potassium of 3.6 mEq/L is actually low-normal — spironolactone will tend to raise it, which is beneficial; the ARR borderline elevation is consistent with the PATHWAY-2 observation that MRA response is strongest in low-renin, borderline aldosterone-excess patients who do not meet formal primary aldosteronism criteria
B) Add bisoprolol 5 mg daily — PATHWAY-2 showed bisoprolol as the preferred fourth-line agent in patients with low PRA because low renin indicates high sympathetic tone requiring adrenergic blockade
C) Add doxazosin 4 mg daily — PATHWAY-2 established doxazosin as equally effective to spironolactone in resistant hypertension and it avoids the hyperkalemia risk of MRA therapy
D) Add eplerenone 50 mg daily rather than spironolactone — eplerenone was the MRA tested in PATHWAY-2 and has stronger evidence than spironolactone in resistant hypertension specifically
E) Withhold fourth-line therapy until formal primary aldosteronism has been confirmed by adrenal vein sampling — PATHWAY-2 only demonstrated MRA benefit in patients with confirmed primary aldosteronism, not in those with borderline ARR
ANSWER: A
Rationale:
PATHWAY-2 was a randomized crossover trial testing spironolactone, bisoprolol, doxazosin, and placebo as fourth-line agents in patients with true resistant hypertension on three optimized drugs including a diuretic. Spironolactone produced the greatest blood pressure reduction (~8.7 mmHg greater than placebo) and was superior to bisoprolol and doxazosin. Critically, the benefit was most pronounced in patients with low plasma renin activity — exactly this patient's profile. The PATHWAY-2 authors noted that resistant hypertension in this population appears to be driven by subclinical aldosterone excess or aldosterone-mediated volume expansion that does not meet formal criteria for primary aldosteronism — a concept consistent with this patient's borderline ARR and low PRA. Her potassium of 3.6 mEq/L (low-normal, likely driven by chlorthalidone) means spironolactone is actually appropriate — it will raise potassium toward normal while blocking the mineralocorticoid receptor. Monitor potassium and creatinine at 4 weeks.
Option B: Option B is incorrect because low PRA does not indicate high sympathetic tone — it indicates renin suppression from volume expansion; bisoprolol was inferior to spironolactone in PATHWAY-2.
Option C: Option C is incorrect because doxazosin was inferior to spironolactone in PATHWAY-2 and is not equally effective.
Option D: Option D is incorrect because PATHWAY-2 used spironolactone, not eplerenone; spironolactone is the evidence-based first choice in resistant hypertension.
Option E: Option E is incorrect because PATHWAY-2 enrolled patients without formal primary aldosteronism diagnosis — the benefit in low-renin patients does not require confirmed primary aldosteronism, and adrenal vein sampling is not a prerequisite for fourth-line MRA therapy in resistant hypertension.
8. A 59-year-old man with hypertension and type 2 diabetes (HbA1c 8.1%) is referred after developing serum potassium of 2.9 mEq/L on hydrochlorothiazide 25 mg daily and lisinopril 20 mg daily. He is asymptomatic. His BP is 134/82 mmHg on the current regimen. His eGFR is 64 mL/min/1.73m2 and UACR is 68 mg/g. Which of the following most completely addresses the hypokalemia while maintaining blood pressure control and metabolic safety?
A) Discontinue lisinopril and increase HCTZ to 50 mg daily — higher doses of thiazide provide better natriuresis and paradoxically reduce potassium wasting through a ceiling effect
B) Add furosemide 20 mg to his current regimen — loop diuretics cause less potassium wasting than thiazides at equivalent antihypertensive doses and will improve the electrolyte balance
C) Switch HCTZ to chlorthalidone 12.5 mg daily and add potassium chloride supplementation — chlorthalidone's longer duration of action provides superior BP control while KCl directly replaces the lost potassium
D) Increase lisinopril to 40 mg daily — maximum-dose RAAS inhibition blunts aldosterone-mediated potassium wasting more effectively than lower doses, correcting the hypokalemia without any other changes
E) Switch HCTZ to chlorthalidone 12.5 mg daily (superior 24-hour BP coverage at lower equivalent dose, potentially less hypokalemia burden), increase lisinopril to 40 mg daily (maximum RAAS inhibition blunts aldosterone-driven potassium wasting from the thiazide), and supplement potassium if needed; check electrolytes at 2 weeks; consider adding amlodipine rather than increasing the thiazide dose if additional BP control is subsequently needed
ANSWER: E
Rationale:
This patient has significant hypokalemia (2.9 mEq/L) despite being on a RAAS inhibitor, suggesting the HCTZ 25 mg dose is generating more potassium wasting than the lisinopril 20 mg can offset. The comprehensive approach addresses multiple levers simultaneously. Switching to chlorthalidone 12.5 mg — a lower absolute dose with equivalent or superior antihypertensive effect — may reduce the potassium wasting burden while improving 24-hour BP coverage. Maximizing lisinopril to 40 mg increases aldosterone suppression and therefore blunts the RAAS-mediated potassium secretion that thiazides stimulate. Potassium supplementation bridges any residual deficit while pharmacological adjustments take effect. Electrolyte monitoring at 2 weeks confirms the response. If additional antihypertensive effect is ever needed, adding amlodipine (potassium-neutral) is far preferable to increasing the thiazide dose (which would worsen hypokalemia). Option C addresses part of the problem but omits maximizing RAAS inhibition, which is pharmacologically the most important intervention for preventing ongoing potassium loss. Option D addresses the RAAS inhibitor dose but does not address the HCTZ formulation issue or the immediate potassium deficit.
Option A: Option A is incorrect because increasing HCTZ to 50 mg will worsen hypokalemia — antihypertensive effect plateaus above 25 mg while adverse metabolic effects increase; discontinuing the RAAS inhibitor removes the primary potassium-protective mechanism.
Option B: Option B is incorrect because furosemide causes greater potassium wasting than thiazides at comparable antihypertensive doses and would worsen the hypokalemia.
9. A 65-year-old man with hypertension, permanent atrial fibrillation, and no history of heart failure presents for medication review. His current regimen is diltiazem extended-release 240 mg daily (for rate control in AF) and lisinopril 20 mg daily. His BP is 148/86 mmHg. His heart rate is 68 bpm. His potassium is 4.4 mEq/L and eGFR is 66 mL/min/1.73m2. His physician wants to add a third antihypertensive agent. Which of the following is the most appropriate choice?
A) Add metoprolol succinate 25 mg daily — a low-dose beta-blocker can be combined with diltiazem to provide additional rate control and blood pressure reduction in atrial fibrillation
B) Add amlodipine 5 mg daily — a DHP CCB is pharmacologically appropriate here because it does not interact with the cardiac nodal tissue that diltiazem already affects; it provides additional antihypertensive efficacy through peripheral arteriolar dilation without affecting heart rate or AV conduction; the combination of a non-DHP CCB plus a DHP CCB is not contraindicated (unlike non-DHP CCB plus beta-blocker)
C) Add verapamil 120 mg twice daily — combining two non-DHP CCBs provides superior rate control compared to diltiazem alone and adds antihypertensive benefit
D) Add bisoprolol 5 mg daily — a cardioselective beta-blocker can be safely combined with diltiazem for dual rate control, and the combination is standard of care in atrial fibrillation requiring strict rate targets
E) Add chlorthalidone 12.5 mg daily only after discontinuing diltiazem — thiazide diuretics interact with non-DHP CCBs through combined effects on renal calcium handling, requiring substitution rather than addition
ANSWER: B
Rationale:
This patient is on diltiazem (a non-DHP CCB) and needs additional blood pressure control. The key pharmacological constraint is that diltiazem cannot be combined with a beta-blocker — this combination produces additive AV nodal suppression (the same contraindication as verapamil plus beta-blocker). Adding amlodipine, a DHP CCB, is safe and pharmacologically rational: dihydropyridines act primarily on vascular smooth muscle calcium channels with minimal cardiac nodal effect, so they do not compound diltiazem's AV nodal suppression. The combination of a non-DHP CCB plus a DHP CCB (e.g., diltiazem plus amlodipine) is used clinically in patients with both rate control needs and difficult-to-control hypertension, though blood pressure, heart rate, and cardiac function should be monitored.
Option A: Option A is incorrect because adding a beta-blocker to diltiazem (a non-DHP CCB) creates the same contraindicated additive AV nodal suppression risk as adding it to verapamil — this is explicitly contraindicated.
Option C: Option C is incorrect because combining two non-DHP CCBs (diltiazem plus verapamil) would produce additive negative chronotropy, negative inotropy, and AV nodal suppression — a dangerous combination.
Option D: Option D is incorrect for the same reason as A — bisoprolol is a beta-blocker and its combination with diltiazem risks severe bradycardia and heart block.
Option E: Option E is incorrect because there is no pharmacological interaction between thiazide diuretics and non-DHP CCBs through renal calcium handling that requires drug substitution; chlorthalidone can be added to diltiazem without discontinuing diltiazem.
10. A 44-year-old woman with a 10-year history of recurrent calcium oxalate kidney stones and newly diagnosed hypertension (BP 152/94 mmHg) presents for initial antihypertensive selection. Her 24-hour urine calcium is 420 mg/day (elevated). Her eGFR is 78 mL/min/1.73m2 and serum calcium is normal. She has no diabetes, no heart failure, and no CKD beyond the hypercalciuria. Which of the following antihypertensive selection and monitoring strategy is most appropriate?
A) Initiate amlodipine 5 mg daily — CCBs are the preferred first-line agent in hypercalciuric nephrolithiasis because they block the calcium channels responsible for urinary calcium secretion in the proximal tubule
B) Initiate furosemide 20 mg daily — loop diuretics actively promote calciuresis and are therefore the most beneficial agent in hypercalciuria-associated nephrolithiasis, providing both antihypertensive and stone-preventive benefit
C) Initiate lisinopril 10 mg daily — ACE inhibitors are preferred in hypercalciuric nephrolithiasis because they reduce glomerular filtration pressure and thereby lower the filtered calcium load driving stone formation
D) Initiate chlorthalidone 12.5 mg daily — thiazide-type diuretics are the pharmacological treatment of choice for hypercalciuric calcium nephrolithiasis, reducing urinary calcium through NCC inhibition-driven enhancement of DCT calcium reabsorption; chlorthalidone's longer half-life provides sustained hypocalciuric effect; monitor 24-hour urine calcium at 8 weeks to confirm reduction; check serum calcium at 4 weeks (thiazides can unmask primary hyperparathyroidism by reducing urinary calcium excretion and raising serum calcium)
E) Initiate spironolactone 25 mg daily — mineralocorticoid receptor antagonism reduces the aldosterone-driven intestinal calcium absorption that causes hypercalciuria in most stone-forming patients
ANSWER: D
Rationale:
Chlorthalidone is the pharmacological agent of choice for a hypertensive patient with hypercalciuria and recurrent calcium nephrolithiasis. The mechanism is well established: NCC inhibition in the DCT lowers intracellular sodium in tubular cells, enhancing the electrochemical gradient that drives passive transcellular calcium reabsorption via TRPV5 channels. Net urinary calcium excretion falls — directly reducing the supersaturation that drives calcium oxalate and calcium phosphate crystal nucleation. Chlorthalidone is preferred over HCTZ because its longer half-life (~40–60 hours vs. HCTZ's 10–12 hours) provides sustained hypocalciuric effect throughout the 24-hour period. Monitoring strategy: 24-hour urine calcium at 8 weeks confirms the therapeutic reduction in urinary calcium; serum calcium at 4 weeks is important because thiazides reduce urinary calcium excretion and can unmask previously subclinical primary hyperparathyroidism (elevated serum calcium on thiazide therapy should prompt PTH measurement).
Option A: Option A is incorrect because CCBs act on vascular and cardiac calcium channels, not on renal tubular calcium transport channels; amlodipine does not reduce urinary calcium excretion.
Option B: Option B is incorrect because loop diuretics increase urinary calcium excretion (calciuria) — the opposite of what is needed; they would accelerate stone formation and worsen hypercalciuria.
Option C: Option C is incorrect because ACE inhibitors do not have a specific effect on tubular calcium reabsorption that meaningfully reduces urinary calcium through a glomerular pressure mechanism.
Option E: Option E is incorrect because spironolactone does not reduce intestinal calcium absorption through an aldosterone-receptor mechanism; this is not an established property of MRA therapy in nephrolithiasis.
11. A 71-year-old man with long-standing hypertension, HFrEF (EF 35%), permanent atrial fibrillation, type 2 diabetes, and stage 3a CKD (eGFR 52 mL/min/1.73m2) is on carvedilol 12.5 mg twice daily, sacubitril/valsartan 97/103 mg twice daily, spironolactone 25 mg daily, and empagliflozin 10 mg daily. His BP is 146/84 mmHg. His heart rate is 72 bpm. Potassium is 5.0 mEq/L and creatinine is 1.6 mg/dL. He has no peripheral edema. His physician wants to add an antihypertensive agent to reach BP target. Which of the following is the most appropriate addition given the full complexity of this regimen?
A) Add verapamil 120 mg twice daily — a non-DHP CCB provides both rate control in AF and blood pressure reduction, addressing two therapeutic goals simultaneously in this patient
B) Add chlorthalidone 12.5 mg daily — at eGFR 52 thiazide-type diuretics retain partial efficacy and are the preferred diuretic add-on; empagliflozin's SGLT2-mediated glycosuria does not interact with thiazide NCC inhibition
C) Add amlodipine 5 mg daily — amlodipine is the only CCB appropriate in HFrEF (V-HeFT III; hemodynamically neutral), is safe at eGFR 52 without renal dose adjustment, does not affect potassium (already at 5.0 mEq/L on spironolactone plus sacubitril/valsartan — any potassium-raising agent is dangerous), does not interact adversely with carvedilol (DHP CCB plus beta-blocker is safe), and provides effective additional blood pressure reduction without worsening cardiac function
D) Add spironolactone dose increase to 50 mg daily — doubling the spironolactone dose will provide additional blood pressure reduction through enhanced MR blockade and is appropriate since his potassium is currently acceptable at 5.0 mEq/L
E) Add furosemide 20 mg daily — at eGFR 52 loop diuretics are required as the primary diuretic; empagliflozin's osmotic diuretic effect is insufficient for volume control in HFrEF and a loop diuretic is needed
ANSWER: C
Rationale:
This is a complex multi-comorbidity patient where every additional agent must be evaluated for compatibility with an already complex regimen. The key constraints: (1) carvedilol (beta-blocker) is present — no non-DHP CCB can be added without risking severe bradycardia and heart block; (2) HFrEF (EF 35%) — non-DHP CCBs (verapamil, diltiazem) are contraindicated; (3) potassium is already 5.0 mEq/L on sacubitril/valsartan plus spironolactone — any potassium-raising agent is dangerous (no dose increase of spironolactone, no additional MRA, careful with RAAS modifications); (4) eGFR 52 — thiazides retain partial efficacy but amlodipine requires no renal dose adjustment and avoids any electrolyte risk; (5) empagliflozin is already providing modest natriuresis and BP reduction through its SGLT2 mechanism. Amlodipine is the single agent that satisfies all constraints: hemodynamically neutral in HFrEF (V-HeFT III), safe with carvedilol (DHP CCB plus beta-blocker is not contraindicated), no potassium effect, no renal dose adjustment, no interaction with the existing complex regimen.
Option A: Option A is incorrect because adding verapamil to carvedilol is the most dangerous possible choice in this regimen — additive AV nodal suppression plus worsened negative inotropy in HFrEF; this is doubly contraindicated.
Option B: Option B is incorrect because while chlorthalidone retains partial efficacy at eGFR 52, the potassium of 5.0 mEq/L on spironolactone plus sacubitril/valsartan means chlorthalidone's potassium-wasting effect may be beneficial, but the primary concern is that the patient has no edema and no clear diuretic indication; amlodipine is the cleaner choice.
Option D: Option D is incorrect because increasing spironolactone to 50 mg with potassium already at 5.0 mEq/L on sacubitril/valsartan and spironolactone creates serious hyperkalemia risk.
Option E: Option E is incorrect because this patient has no edema and no volume overload; adding furosemide without an indication risks volume depletion, and empagliflozin's SGLT2 mechanism is not a reason to add a loop diuretic prophylactically.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.